Effects of Vitamin D Supplementation on Immune Function in Infants

July 1, 2020 updated by: Shih Chien University
Current study shows that vitamin D deficiency might affect human's immune function. Although breast milk is the best food of infants, however the vitamin D content in breast milk is low. Thus, breastfeeding infants are at high risk of vitamin D deficiency.Children's development and health are always the most important issues for parents. However, high prevalence of allergy in infants in Taiwan were not only with environmental factor which may also relate to their nutritional status. The aim of this study was to enroll breastfeeding infant at age of 4 month, and provide vitamin D supplement 10 μg daily until 6 month, to discuss the effects of vitamin D supplementation on immune function in infants.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Study plan to enroll breastfeeding infant at age of 4 month, and provide vitamin D (vitD) supplement 10 μg daily until 6 month. we also enroll 6 month-old infant as control group.

All infants collected 5 ml artery blood and measured vitD nutritional status and immune function. Blood analysis contain complete blood count (CBC), differential count (DC), serum calcium, serum Parathyroid hormone (PTH), serum 25(OH)D3, serum total immunoglobulinE (IgE) and cell phagocytosis.

Peripheral blood mononuclear cell (PBMC) in blood was separated and cultured with complete medium contain 10% fetal bovine serum (CM10), or with different mitogens, include lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate and ionomycin (PI) and house dust mite extract (HDM). PBMC are incubated at 37 ℃, 5% CO2 for 48 hours, and determined the expression of B cell with IgE receptor CD21 and CD23 and T regulatory cell with transcription factor Foxp3 by flow cytometry. All data were analyzed with SPSS 20.0. Infant sex and feeding type were analyzed by chi-square analysis. Difference between vitD supplement group and control group were analyzed by student's t test. Relationship between 25(OH)D3 and Calcium or PTH were analyzed by pearson correlation analysis. There was a significant difference when p-value was less than 0.05.

Study Type

Interventional

Enrollment (Actual)

59

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan, 104
        • Shih Chien University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 months to 6 months (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Breastfeeding healthy infants

Exclusion Criteria:

  • heart disease
  • liver disease
  • lung disease
  • Intestinal disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Enroll 6 months old breast feeding infant, who have not supplement vitamin D at pediatric clinic.
Experimental: VitD supplement
Enroll 4 months old breast feeding infant, and provide 10 μg vitamin D daily for 2 months.
vitamin D supplement 10 μg daily for 2 months
Other Names:
  • Baby Ddrops® Liquid Vitamin D3 Vitamin Supplement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characteristic of infants-1
Time Frame: Infants at 4 months old
Gender in baseline
Infants at 4 months old
Characteristic of infants-2
Time Frame: Infants at 4 months old
Gestational week (week) in baseline
Infants at 4 months old
Characteristic of infants-3
Time Frame: Infants at 4 months old
Birth length (cm) in baseline
Infants at 4 months old
Characteristic of infants-4
Time Frame: Infants at 4 months old
Birth weight (kg) in baseline
Infants at 4 months old
Characteristic of infants-5
Time Frame: Infants at 4 months old
Birth head circumference (cm) in baseline
Infants at 4 months old
Characteristic of infants-6
Time Frame: Infants at 4 months old
Exposed to the sun (min/day) in baseline
Infants at 4 months old
Characteristic of infants-7
Time Frame: Infants at 4 months old
Exclusive breast-fed n (%) in baseline
Infants at 4 months old
Characteristic of infants-8
Time Frame: Infants at 4 months old
Mixed-fed n (%) in baseline
Infants at 4 months old
The anthropometric of infants from 4 months old to 6 months old-1
Time Frame: Infants at 4 and 6 months old
Length percentile (%) in both groups
Infants at 4 and 6 months old
The anthropometric of infants from 4 months old to 6 months old-2
Time Frame: Infants at 4 and 6 months old
Weight percentile (%) in both groups
Infants at 4 and 6 months old
Vitamin D nutritional status of infants-1
Time Frame: Infants at 4 and 6 months old
Ca (mg/dL) in both groups
Infants at 4 and 6 months old
Vitamin D nutritional status of infants-2
Time Frame: Infants at 4 and 6 months old
PTH (pg/mL) in both groups
Infants at 4 and 6 months old
Vitamin D nutritional status of infants-3
Time Frame: Infants at 4 and 6 months old
25(OH)D3 (ng/mL) in both groups
Infants at 4 and 6 months old

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cell markers expression of B cells
Time Frame: Infants at 6 months old
D21 and CD23 expression (%) in both groups
Infants at 6 months old
Cell markers expression of T cells
Time Frame: Infants at 6 months old
Foxp3 expression (%) in both groups
Infants at 6 months old
Serum immunoglobulin E level of infants
Time Frame: Infants at 6 months old
Concentration of IgE (ng/ml) in both groups
Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by CM-10 induction-1
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-6 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by CM-10 induction-2
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-4 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by CM-10 induction-3
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-13 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by CM-10 induction-4
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-10 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by CM-10 induction-5
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of TGF-β (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by LPS induction-1
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-6 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by LPS induction-2
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of TNF-α (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by PI induction-1
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-4 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by PI induction-2
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-13 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by PI induction-3
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-10 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by PI induction-4
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of TGF-β (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by HDM induction-1
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IFN-γ (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by HDM induction-2
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-4 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by HDM induction-3
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-13 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by HDM induction-4
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of IL-10 (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old
Cytokine levels in supernatant of lymphocyte by HDM induction-5
Time Frame: Lymphocyte isolation from Infants at 6 months old
Concentration of TGF-β (pg/ml) in both groups
Lymphocyte isolation from Infants at 6 months old

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Chao-Ming Chen, MD/PHD, Shih Chien University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 18, 2015

Primary Completion (Actual)

June 17, 2016

Study Completion (Actual)

December 30, 2016

Study Registration Dates

First Submitted

July 24, 2017

First Submitted That Met QC Criteria

July 1, 2020

First Posted (Actual)

July 8, 2020

Study Record Updates

Last Update Posted (Actual)

July 8, 2020

Last Update Submitted That Met QC Criteria

July 1, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vitamin D Deficiency

Clinical Trials on vitamin D

Subscribe